Influence of primate lentiviral vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G

被引:119
作者
Liu, BD
Yu, XH
Luo, K
Yu, YK
Yu, XF
机构
[1] Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[2] Zhejiang Univ, Zhejiang, Peoples R China
关键词
D O I
10.1128/JVI.78.4.2072-2081.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for viral evasion of the host antiviral protein APOBEC3G, also known as CEM15. Vif mutant but not wild-type HIV-1 viruses produced in the presence of APOBEC3G have been shown to undergo hypermutations in newly synthesized viral DNA upon infection of target cells, presumably resulting from C-to-U modification during minus-strand viral DNA synthesis. We now report that HIV-1 Vif could induce rapid degradation of human APOBEC3G that was blocked by the proteasome inhibitor MG132. The efficiency of Vif-induced downregulation of APOBEC3G expression depended on the level of Vif expression. A single amino acid substitution in the conserved SLQXIA motif reduced Vif function. Vif proteins from distantly related primate lentiviruses such as SIVagm were unable to suppress the antiviral activity of human APOBEC3G or the packaging of APOBEC3G into HIV-1 Vif mutant virions, due to a lack of interaction with human APOBEC3G. In the presence of the proteasome inhibitor MG132, virion-associated Vif increased dramatically. However, increased virion packaging of Vif did not prevent virion packaging of APOBEC3G when proteasome function was impaired, and the infectivity of these virions was significantly reduced. These results suggest that Vif function is required during virus assembly to remove APOBEC3G from packaging into released virions. Once packaged, virion-associated Vif could not efficiently block the antiviral activity of APOBEC3G.
引用
收藏
页码:2072 / 2081
页数:10
相关论文
共 66 条
[31]   Hypermutation of HIV-1 DNA in the absence of the Vif protein [J].
Lecossier, D ;
Bouchonnet, F ;
Clavel, F ;
Hance, AJ .
SCIENCE, 2003, 300 (5622) :1112-1112
[32]   A NEW HTLV-III/LAV PROTEIN ENCODED BY A GENE FOUND IN CYTOPATHIC RETROVIRUSES [J].
LEE, TH ;
COLIGAN, JE ;
ALLAN, JS ;
MCLANE, MF ;
GROOPMAN, JE ;
ESSEX, M .
SCIENCE, 1986, 231 (4745) :1546-1549
[33]   Identification and characterization of virus assembly intermediate complexes in HIV-infected CD4+ T cells [J].
Lee, YM ;
Yu, XF .
VIROLOGY, 1998, 243 (01) :78-93
[34]   THE VIF PROTEIN OF HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUSES IS PACKAGED INTO VIRIONS AND ASSOCIATES WITH VIRAL CORE STRUCTURES [J].
LIU, HM ;
WU, XY ;
NEWMAN, M ;
SHAW, GM ;
HAHN, BH ;
KAPPES, JC .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7630-7638
[35]   Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA [J].
Lockridge, KM ;
Chien, M ;
Dean, GA ;
Cole, KS ;
Montelaro, RC ;
Luciw, PA ;
Sparger, EE .
VIROLOGY, 2000, 273 (01) :67-79
[36]   An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein [J].
Madani, N ;
Kabat, D .
JOURNAL OF VIROLOGY, 1998, 72 (12) :10251-10255
[37]   Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts [J].
Mangeat, B ;
Turelli, P ;
Caron, G ;
Friedli, M ;
Perrin, L ;
Trono, D .
NATURE, 2003, 424 (6944) :99-103
[38]   Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif [J].
Mariani, R ;
Chen, D ;
Schröfelbauer, B ;
Navarro, F ;
König, R ;
Bollman, B ;
Münk, C ;
Nymark-McMahon, H ;
Landau, NR .
CELL, 2003, 114 (01) :21-31
[39]   HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation [J].
Marin, M ;
Rose, KM ;
Kozak, SL ;
Kabat, D .
NATURE MEDICINE, 2003, 9 (11) :1398-1403
[40]   THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) VIF PROTEIN IS LOCATED IN THE CYTOPLASM OF INFECTED-CELLS AND ITS EFFECT ON VIRAL REPLICATION IS EQUIVALENT IN HIV-2 [J].
MICHAELS, FH ;
HATTORI, N ;
GALLO, RC ;
FRANCHINI, G .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (10) :1025-1030